Pass The Study: An Injected Stem Cell for Patients with Geographic Atrophy
In the first episode of this new game show, a team of ARVO 2022 investigators work to invent an innovative clinical trial.
Welcome to Pass the Study, the show where clinical researchers work together to propose a new study for their field in a few simple steps. The catch? They don’t know who their co-authors are, and they can only add on to what previous authors put in the trial.
Over the week during the Association for Research in Vision and Ophthalmology (ARVO) 2022 Meeting, HCPLive managing editor Kevin Kunzmann spoke with various trial investigators and study presenters throughout retina care.
Today, in the first episode of Pass the Study, this first group of ophthalmologists work together to establish a trial for a novel, groundbreaking injectable stem cell therapy for patients with geographic atrophy (GA) and very specific baseline measurements.
The participants include:
- Matthew Cunningham, MD, ophthalmologist at the Florida Retina Institute
- Katerina Prokopiou, PhD, research associate at Ophthalmos Research and Educational Institute and assistant professor in pharmacology at the University of Nicosia Medical School
- Veeral S. Sheth, MD, MBA, director of clinical research at the University of Retina and Macula Associates
- Arshad Khanani, MD, MA, director of clinical research, Sierra Eye Associates
- Theodore Leng, MD, MS, associate professor of ophthalmology, Stanford University
Watch the video above as the first 4 investigators work together to create a patient population, trial methods, an intervention and key endpoints—before Leng is tasked with reviewing the piecemeal study.
Check out the rest of the HCPLIve coverage of ARVO 2022 here.
